Information  X 
Enter a valid email address

Lipoxen PLC (XEN)

  Print      Mail a friend

Friday 13 August, 2010

Lipoxen PLC

Founder Receives Prestigious

RNS Number : 0209R
Lipoxen PLC
13 August 2010
 



For immediate release

RNS Reach

13 August 2010

 

 

 

Lipoxen plc

 

('Lipoxen' or 'the Company')

 

Founder Gregory Gregoriadis Receives Prestigious Award

- Recognition for 40 years of service within the field of Liposome technology -

 

 

Lipoxen plc (AIM: LPX), a bio-pharmaceutical company specialising in the development of high-value differentiated biologicals, vaccines and siRNA delivery, is delighted to announce that its founder and Chief Scientific Officer, Professor Gregory Gregoriadis has received a special "Founders Award" in recognition of his 40 years of founding the field of liposomes in the delivery of drugs and vaccines, and its promotion over the decades. The award was presented at the recently held international conference at the University of British Columbia in Vancouver, Canada focused on 'Lipids, Liposomes & Membrane Biophysics'.

 

Commenting on the award Professor Gregory Gregoriadis PhD, DSc said: "I am honoured to have been recognised for my work in the extremely exciting field of liposome technology and to have received the Founders Award at this important conference.

 

 

- Ends -

 

For further information, please contact:

Enquiries 

Lipoxen plc

+44 (0)20 7389 5015

M. Scott Maguire, Chief Executive Officer




Singer Capital Markets (nominated adviser)

+44 (0)20 3205 7500

Jeff Keating / Claes Spång




Buchanan Communications

+44 (0)20 7466 5000

Lisa Baderoon, Catherine Breen


 

About Lipoxen

Lipoxen plc is a biopharmaceutical company focused on the development of new and improved biologic drugs and vaccines.  Lipoxen has three proprietary patented technology platforms:

 

1) PolyXen - for extending the efficacy and half life of biologic drugs

2) ImuXen - for creating new vaccines and improving existing vaccines

3) SiRNAblate - for the delivery of siRNA

 

Lipoxen's technology is designed to improve the efficacy, safety, stability, biological half-life and immunologic characteristics of its products. 

 

Lipoxen has multiple drug and vaccine programmes in development.  Two products are in clinical development, SuliXen, a long acting insulin and ErepoXen, a long-acting erythropoietin (EPO). Lipoxen's preclinical pipeline includes vaccines against HIV, influenza and malaria and an exclusive license deal with Baxter Healthcare for blood coagulation drugs.

 

The Company has a low-risk business model and out-licenses its proprietary technologies to biopharmaceutical companies that have strong manufacturing and marketing capabilities.  Lipoxen currently has commercial agreements with some of the world's leading biotechnology and pharmaceutical companies including Baxter, Schering-Plough, the Serum Institute of India Limited, Genentech, and Genzyme. Furthermore, Baxter, the Company's third largest shareholder, and management led the £2.9 million fundraising that the Company announced in May 2009. This fundraising was followed up by a £1.2 million placing in April 2010 which was led by the Company's management team.

 

Lipoxen, which was founded in 1997, trades on the AIM Market of the London Stock Exchange under the ticker symbol LPX. More information can be found at the Company's website: www.lipoxen.com.

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAQLLFFBVFXBBZ